NanoViricides to build cGMP production and laboratory facility in US
Facility will produce drug substances for human clinical trials
NanoViricides, a US developer of drugs to tackle virus particles, has retained Id3A as the architect for its laboratory and cGMP pilot production facility project. This completes the architecture, design and construction management team, which includes project management and design engineer MPH Engineering.
This facility will be built by renovating an existing 18,000ft2 light manufacturing plant in Shelton, CT, US.
Id3A will be responsible for the overall facility architecture, including integration of a separately constructed cleanroom suite for cGMP production.
The cGMP pilot plant is being designed for the production of sufficient quantities of the drug needed for human clinical trials for each of the various nanoviricides drug candidates as they advance into the clinical pipeline.
The drug substance produced in this facility will then be delivered to a third party for final processing and labelling, as required, for human clinical trials when ready.
The light industrial building was bought by Inno-Haven, a private company founded by CEO Anil Diwan, with the specific purpose of enabling clinical cGMP manufacturing capabilities for NanoViricides’ drug substances. NanoViricides expects to lease this facility.
NanoViricides is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
The company completed US$5m in financing by receiving the final tranche of $2.5m from investor Seaside 88 in December 2012.
The funding will allow NanoViricides to meet the cost of certain additional equipment needed for the facility.
“This financing is very important for the company as we advance our influenza drug candidate towards IND stage and future human clinical trials. It will also help us to continue to move forward with all of the drug programmes in our broad pipeline,” said Diwan.
